NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025.
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
Seeking Alpha / 36 minutes ago 2 Views
Comments